Published by Global Banking and Finance Review
Posted on February 3, 2025
3 min readLast updated: January 26, 2026
Novo Nordisk Foundation will not fill the gap left by the US aid freeze, focusing instead on non-communicable diseases like diabetes and heart disease.
By Jennifer Rigby
LONDON (Reuters) - The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a freeze on U.S.-funded foreign aid, and will continue to focus on its core non-communicable disease agenda, an official told Reuters.
The foundation, which is linked to the Danish drugmaker and is one of the world's largest charitable organizations, will prioritize funding work tackling conditions such as heart disease and diabetes, and risk factors like obesity, said Flemming Konradsen, scientific director of global health.
“Of course, more people are contacting us... We don’t have plans of stepping in, of filling gaps,” Konradsen said in an interview last week, when asked who could step in as governments rein in global health spending.
Since President Donald Trump took office on Jan. 20, the U.S. has frozen international aid, although some waivers for lifesaving assistance have been put in place. It will also quit the World Health Organization, news that sent shockwaves worldwide.
The foundation is the parent company of Novo Holdings, the controlling shareholder of Novo Nordisk, which makes the blockbuster obesity drug Wegovy and diabetes medication.
Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although investments have moved slowly so far. It has $153 billion in total assets, and just under $25 billion available for grants and investments, a spokesperson said.
Konradsen said international grants had increased to around $150 million last year, representing 10-12% of total grants, with the rest of its $1.35 billion allocated to work in Denmark and other Nordic countries.
Internationally, he said the biggest focus would be on helping governments implement healthy school meal programs, and to support institutions that train nurses.
“Chronic diseases are simply breaking the bank,” he said.
Global health experts have questioned what other wealthy philanthropies could do to mitigate the impact of the U.S. government’s actions.
Rob Nabors, who leads the Gates Foundation’s North America government relations, policy and advocacy efforts, said there was no foundation “that can provide the funding, workforce capacity, expertise, or leadership that the United States has historically provided to combat and control deadly diseases and address hunger and poverty around the world.”
A spokeswoman declined to comment on whether the Gates Foundation might expand funding for such programs.
(Reporting by Jennifer Rigby, editing by Michele Gershberg and Bernadette Baum)
The Novo Nordisk Foundation does not plan to step in to support the global health sector affected by the U.S. aid freeze and will maintain its focus on core health issues.
Since President Trump took office, the U.S. has frozen international aid, which has raised concerns about the ability of wealthy philanthropies to fill the gaps left by this funding cut.
The foundation prioritizes funding for conditions like heart disease and diabetes, and aims to implement healthy school meal programs and support nurse training.
Last year, the foundation increased its international grants to around $150 million, which represented 10-12% of its total grants.
Chronic diseases are significantly straining healthcare systems, as highlighted by Konradsen, who noted that they are 'breaking the bank.'
Explore more articles in the Headlines category
